$QURE news
The latest QURE stock news: headlines, filings, AI summaries and sentiment for $QURE, updated around the clock.
- uniQure Reports Q3 2026 Financial Results and AMT-130 Clinical Updates
- uniQure Receives FDA Priority Review for AMT-130 with PDUFA Date Set for May 2027
- uniQure Reports Q3 Results with EPS Beat and Revenue Growth Amid Cash Runway Extension
- uniQure N.V. - 8-K Filing
- uniQure (QURE) Scheduled to Report Q3 2026 Earnings on November 4
- FDA Grants Priority Review for uniQure's Huntington's Disease Gene Therapy
- uniQure N.V. - 8-K Filing
- Pomerantz Law Firm Investigates Potential Securities Fraud at ClearPoint Neuro, Inc.
- uniQure N.V. - 8-K Filing
- Wall Street Analysts Upgrade Humana, Downgrade Las Vegas Sands
- uniQure Reports GAAP EPS of -$1.22, Revenue Beats Estimates
- uniQure N.V. - 10-Q Filing
- uniQure N.V. - 8-K Filing
- Barclays Upgrades UniQure N.V. (QURE) to Overweight Amid Advancements in Huntington's Disease Program
- uniQure Announces $150M Public Offering of Ordinary Shares
- uniQure N.V. - 8-K Filing
- UniQure (QURE) Shares Rise 78% Following FDA Acceptance of AMT-130 Clinical Data
- Stocks Rise on Chip Sector Strength and Stronger-than-Expected U.S. Retail Sales
- Uniqure NV (QURE) Announces Plans to Seek UK Approval for AMT-130 Gene Therapy